Bellicum Pharmaceuticals Reports First Quarter 2018 Financial Results Read more about Bellicum Pharmaceuticals Reports First Quarter 2018 Financial Results
Bellicum Pharmaceuticals Announces Closing of Public Offering Read more about Bellicum Pharmaceuticals Announces Closing of Public Offering
Bellicum Pharmaceuticals Announces Pricing of Public Offering of Common Stock Read more about Bellicum Pharmaceuticals Announces Pricing of Public Offering of Common Stock
Bellicum Pharmaceuticals Announces Proposed Public Offering of Common Stock Read more about Bellicum Pharmaceuticals Announces Proposed Public Offering of Common Stock
Bellicum Announces Clinical Hold Lifted on U.S. Studies of BPX-501 Read more about Bellicum Announces Clinical Hold Lifted on U.S. Studies of BPX-501
Bellicum Pharmaceuticals Provides Operational Update and Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2017 Read more about Bellicum Pharmaceuticals Provides Operational Update and Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2017
Bellicum Announces Interim Results Showing Low Rates of Cancer Recurrence in Pediatric AML Patients Treated with BPX-501 Read more about Bellicum Announces Interim Results Showing Low Rates of Cancer Recurrence in Pediatric AML Patients Treated with BPX-501
Bellicum Pharmaceuticals to Report Fourth Quarter and Full Year 2017 Financial Results and Host Conference Call and Webcast on March 13, 2018 Read more about Bellicum Pharmaceuticals to Report Fourth Quarter and Full Year 2017 Financial Results and Host Conference Call and Webcast on March 13, 2018
Bellicum Announces Update on Clinical Hold of U.S. BPX-501 Studies Read more about Bellicum Announces Update on Clinical Hold of U.S. BPX-501 Studies
Bellicum Pharmaceuticals Appoints Edmund P. Harrigan, M.D. to its Board of Directors Read more about Bellicum Pharmaceuticals Appoints Edmund P. Harrigan, M.D. to its Board of Directors